TrialBlood advances2022

Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.

Cara A Rosenbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.